Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer
Anticancer Research · 2024
DOI: 10.21873/anticanres.16877 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Makoto Nakao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Japan; kokoro1979@gmai…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: Pretreatment serum cytokeratin 19 fragment (CYFRA21-1) level predicts outcomes in patients with non-small cell lung cancer; however, little is known about the clinical value of serum CYFRA21-1 level in patients with small cell lung cancer (SCLC). The aim of this study was to evaluate the prognostic value of pretreatment serum CYFRA21-1 level in patients with extensive disease (ED)-SCLC treated using platinum-doublet chemotherapy. PATIENTS AND METHODS: We retrospectively analyzed the pretreatment serum CYFRA21-1 levels of patients with ED-SCLC who were treated using first-line platinum-doublet chemotherapy. RESULTS: A total of 98 patients were analyzed. The patients with a high CYFRA21-1 level (≥7.0 ng/ml) (n=29) had significantly shorter progression-free survival (PFS) and overall survival (OS) than the patients with low CYFRA21-1 levels (n=67) [median PFS=118 days vs. 125 days, respectively (p=0.018); median OS=213 days vs. 295 days, respectively (p=0.046)]. In addition, high CYFRA21-1 level was associated with a high refractory relapse rate. CONCLUSION: Serum CYFRA21-1 level may be a prognostic marker for patients with ED-SCLC treated with platinum-doublet chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Japan; kokoro1979@gmail.com.
- Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Japan.
- Department of Radiation Oncology, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Japan.
Zitieren
APA
Nakao, M., Kinoshita, R., Kuriyama, M., Kiyotoshi, H., Sugihara, M., Takeda, N., Ohtakara, K., & Muramatsu, H. (2024). Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.16877
Vancouver
Nakao M, Kinoshita R, Kuriyama M, Kiyotoshi H, Sugihara M, Takeda N, et al. Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer. Anticancer Research. 2024. doi:10.21873/anticanres.16877
BibTeX
@article{Nakao2024,
author = {Nakao, Makoto and Kinoshita, Ryosuke and Kuriyama, Mamiko and Kiyotoshi, Hiroko and Sugihara, Masahiro and Takeda, Norihisa and Ohtakara, Kazuhiro and Muramatsu, Hideki},
title = {Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.16877}
}
EUVIMED